Skip to main content
main-content

The independent medical news service

Lung cancer

03-12-2018 | Oncology | News | Article

approvalsWatch

Positive FDA decisions for lorlatinib, talazoparib, pembrolizumab

Read more about these approvals here

26-11-2018 | Oncology | News | Article

Adjuvant erlotinib delays recurrence in stage IA–IIIA NSCLC

Adjuvant erlotinib significantly prolongs disease-free survival, compared with a historic benchmark, in patients with epidermal growth factor receptor-mutated stage IA–IIIA non-small-cell lung cancer, US research shows.

Source:

J Clin Oncol 2018; doi:10.1200/JCO. 18.00131

19-11-2018 | Oncology | News | Article

Editor's pick

Clinically important safety differences found among immune checkpoint inhibitors

A network meta-analysis has ranked the safety of immune checkpoint inhibitors in cancer treatment, with atezolizumab revealed to have the best general safety profile.

Source:

BMJ 2018; 363: K4266

13-11-2018 | Lung cancer | Main feed | News

Lorlatinib shows promising activity against ALK-positive advanced NSCLC

Patients with ALK-positive advanced non-small-cell lung cancer respond to the third-generation ALK and ROS1 tyrosine kinase inhibitor lorlatinib irrespective of previous ALK tyrosine kinase inhibitor treatment status, phase II study data show.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30649-1
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30789-7

05-11-2018 | Lung cancer | Main feed | News

NCRI 2018 in brief

Impact of undertreatment on reduced survival in older lung cancer patients quantified

A modeling study presented at the 2018 NCRI Conference in Glasgow, UK, estimates that around 38% of the survival difference between older and younger patients with lung cancer may be due undertreatment in the older age group.

01-11-2018 | Non-small-cell lung cancer | News | Article

Neoadjuvant erlotinib evaluated for EGFR-mutated stage IIIA-N2 NSCLC

The CTONG-1103 EMERGING trial investigators believe that neoadjuvant treatment with epidermal growth factor receptor–tyrosine kinase inhibitors for stage IIIA-N2 non-small-cell lung cancer warrants further investigation.

Source:

ESMO 2018; Munich, Germany; 19–23 October

31-10-2018 | Oncology | News | Article

ESMO 2018

ALESIA confirms first-line alectinib benefit in Asian advanced NSCLC patients

The ALESIA trial comprising treatment-naïve patients with advanced anaplastic lymphoma kinase translocation-positive non-small-cell lung cancer confirms the systemic and intracranial efficacy of alectinib over crizotinib in an Asian population.

Source:

ESMO 2018; Munich, Germany; 19–23 October

19-10-2018 | Non-small-cell lung cancer | News | Article

ESMO 2018

Dual MET–EGFR inhibition promising for relapsed MET-high NSCLC

Combining the highly selective MET inhibitor tepotinib with gefitinib could benefit patients with non-small-cell lung cancer that has progressed on first-line treatment with an EGFR–tyrosine kinase inhibitor and has high levels of MET, suggest phase II trial results.

Source:

ESMO 2018; Munich, Germany; 19–23 October

19-10-2018 | Lung cancer | News | Article

Adding plasma NGS testing to routine NSCLC management could aid targeted therapy delivery

Plasma-based next-generation sequencing may help to identify therapeutically targetable mutations in patients with metastatic non-small-cell lung cancer, suggests research published in JAMA Oncology.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.4305

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.4304

10-10-2018 | Oncology | News | Article

Short-term hospitalization, mortality risk varies by palliative chemotherapy regimen

Two independent studies of older patients receiving initial chemotherapy for metastatic breast cancer or non-small-cell lung cancer have found that the risk for hospitalization or death may be predicted by the cytotoxic regimen used.

Source:

Cancer 2018; doi:10.1002/cncr.31760
JAMA Network Open 2018; 1: e183023

09-10-2018 | Oncology | Main feed | News

approvalsWatch

Brigatinib, paclitaxel, biosimilar pegfilgrastims receive EMA approvals

Read more on these decisions here

04-10-2018 | Oncology | News | Article

Editor's pick

Durvalumab stage III NSCLC benefits extends to overall survival

Updated findings from the PACIFIC trial demonstrate a significant improvement in overall survival with the immune checkpoint inhibitor durvalumab for patients with stage III unresectable non-small-cell lung cancer that has not progressed after concurrent chemoradiotherapy.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1809697

04-10-2018 | Non-small-cell lung cancer | News | Article

News in brief

Hyperprogression, pseudoprogression specific to PD-1 pathway inhibitor therapy

Hyperprogression and pseudoprogression appear to be response patterns that are specific to immunotherapy with inhibitors of programmed cell death protein 1 and its ligand in patients with non-small-cell lung cancer, say researchers.

03-10-2018 | Non-small-cell lung cancer | News | Article

Editor's pick

Brigatinib outplays crizotinib in ALK inhibitor-naïve advanced NSCLC

Treatment with brigatinib is associated with better outcomes than crizotinib in patients with anaplastic lymphoma kinase translocation-positive advanced non-small-cell lung cancer who have not received prior ALK-targeted therapy, indicate phase III trial results.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1810171
WCLC 2018; Toronto, Ontario, Canada

02-10-2018 | Non-small-cell lung cancer | News | Article

News in brief

Surgery type may predict long-term opioid use in early-stage NSCLC

Patients who undergo video-assisted thoracoscopic surgery for stage I non-small-cell lung cancer are less likely to become long-term opioid users than their counterparts undergoing the conventional open procedure, findings suggest.

01-10-2018 | Oncology | Main feed | News

approvalsWatch

Dacomitinib approved for metastatic NSCLC with EGFR activating mutations

Click here to read more on this US FDA announcement

27-09-2018 | Non-small-cell lung cancer | News | Article

No survival benefit seen with avelumab in advanced PD-L1-positive NSCLC

Avelumab has a “favourable” safety profile over docetaxel, but does not improve survival, when used to treat patients with programmed cell death ligand 1-positive advanced non-small-cell lung cancer, say researchers.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30673-9
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30683-1
WCLC 2018; Toronto, Ontario, Canada

26-09-2018 | Non-small-cell lung cancer | News | Article

KEYNOTE-407 supports pembrolizumab–chemotherapy combination for metastatic squamous NSCLC

Survival outcomes are improved with the addition of pembrolizumab to chemotherapy in patients with untreated, metastatic nonsquamous non-small-cell lung cancer, indicate findings from the phase III KEYNOTE-407 trial.

Source:

N Engl J Med 2018; doi:10.1056/NEJMoa1810865

21-09-2018 | Non-small-cell lung cancer | News | Article

Editor's pick

Brigatinib has intracranial activity in patients with ALK-rearranged NSCLC

Patients with anaplastic lymphoma kinase translocation-positive non-small-cell lung cancer that has metastasized to the central nervous system derive benefit from treatment with brigatinib, suggests an analysis of two trials.

Source:

J Clin Oncol 2018; 36: 2677–2679, 2693–2701

18-09-2018 | Oncology | Main feed | News

approvalsWatch

Durvalumab, abemaciclib approvals announced by EMA

Click through to read more

image credits